Related references
Note: Only part of the references are listed.Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G. Till et al.
BLOOD (2008)
Redirecting specificity of T-cell Populations for CD19 using the Sleeping beauty system
Harjeet Singh et al.
CANCER RESEARCH (2008)
Sleeping beauty transposon-mediated engineering of human primary T cells for therapy of CD19(+) lymphoid malignancies
Xin Huang et al.
MOLECULAR THERAPY (2008)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg et al.
NATURE REVIEWS CANCER (2008)
Site-directed transposon integration in human cells
Stephen R. Yant et al.
NUCLEIC ACIDS RESEARCH (2007)
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes
Laura A. Johnson et al.
JOURNAL OF IMMUNOLOGY (2006)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Transposons for gene therapy!
Zoltan Ivics et al.
CURRENT GENE THERAPY (2006)
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability
Cyrille J. Cohen et al.
CANCER RESEARCH (2006)
Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted Sleeping Beauty transposon
Li Liu et al.
MOLECULAR THERAPY (2006)
RNA as a source of transposase for Sleeping Beauty-mediated gene insertion and expression in somatic cells and tissues
A Wilber et al.
MOLECULAR THERAPY (2006)
Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system
X Huang et al.
BLOOD (2006)
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation
YB Zhao et al.
MOLECULAR THERAPY (2006)
Supernatural T cells: Genetic modification of T cells for cancer therapy
MH Kershaw et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR
CJ Cohen et al.
JOURNAL OF IMMUNOLOGY (2005)
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
L Gattinoni et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tunior cell lines
YB Zhao et al.
JOURNAL OF IMMUNOLOGY (2005)
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions
MS Hughes et al.
HUMAN GENE THERAPY (2005)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
ME Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High-resolution genome-wide mapping of transposon integration in mammals
SR Yant et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Target-site preferences of Sleeping Beauty transposons
GY Liu et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
Cooperation of human tumor-reactive CD4(+) and CD8(+) T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR
J Kuball et al.
IMMUNITY (2005)
Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells
G Lizée et al.
HUMAN GENE THERAPY (2004)
Development of hyperactive Sleeping Beauty transposon vectors by mutational analysis
H Zayed et al.
MOLECULAR THERAPY (2004)
Mutational analysis of the N-terminal DNA-binding domain of Sleeping Beauty transposase: Critical residues for DNA binding and hyperactivity in mammalian cells
SR Yant et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector
AL Szymczak et al.
NATURE BIOTECHNOLOGY (2004)
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens
RA Morgan et al.
JOURNAL OF IMMUNOLOGY (2003)
Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence
S Cavalieri et al.
BLOOD (2003)
Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells
XZ Zhou et al.
HUMAN GENE THERAPY (2003)
Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer
S Ortiz-Urda et al.
GENE THERAPY (2003)
Gene transfer into genomes of human cells by the sleeping beauty transposon system
AM Geurts et al.
MOLECULAR THERAPY (2003)
Transcription start regions in the human genome are favored targets for MLV integration
XL Wu et al.
SCIENCE (2003)
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
S Hacein-Bey-Abina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Mechanisms that regulate silencing of gene expression from retroviral vectors
CS Swindle et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2002)
Silencing of gene expression: implications for design of retrovirus vectors
D Pannell et al.
REVIEWS IN MEDICAL VIROLOGY (2001)
Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system
SR Yant et al.
NATURE GENETICS (2000)
Share Paper
